Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Mellitus: An Umbrella Review of Systematic Reviews
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with rising global prevalence, requiring effective management to prevent complications. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including luseogliflozin, are a novel class of drugs that provide benefits beyond glycemic control. This umbrella review synthesized evidence from multiple systematic reviews and meta-analyses to evaluate the efficacy and safety of luseogliflozin in T2DM patients. Following Joanna Briggs Institute (JBI) guidelines and PRISMA standards, eligible studies included systematic reviews and meta-analyses of randomized controlled trials (RCTs) and observational studies involving adult T2DM patients treated with luseogliflozin. A comprehensive literature search was performed in PubMed, EMBASE, and Web of Science up to June 10, 2024. Data extraction and quality assessment were independently conducted by two reviewers, and statistical analyses were performed using R software version 4.3. Fourteen systematic reviews were included, showing that luseogliflozin significantly reduced HbA1c levels (pooled mean difference -1.784, 95% CI: -3.99 to -0.431), fasting plasma glucose (FPG) levels (-3.165, 95% CI: -4.046 to -2.284), and postprandial glucose (PPG) levels (-37.148, 95% CI: -65.361 to -8.935) compared with placebo. Additional benefits included significant reductions in body weight (-1.322 kg, 95% CI: -1.58 to -1.056), triglycerides (-13.891, 95% CI: -26.539 to -1.243), uric acid…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.